Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Add-Aspirin
2024-511306-23-00Phase 3Authorised
- Sponsor
- University College London
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of Cartia in breast cancer, colon cancer, rectal cancer and 3 more (3 arms), sponsored by University College London. Primary endpoints: Overall survival (all participants), Invasive disease-free survival (breast cancer) and 3 more. Planned start Jul 2024; status: authorised.
02
Drugs
Cartia
03
Conditions
breast cancercolon cancerrectal cancergastric cancer (GC)esophageal cancer
Beyond the preview
Go deeper on 2024-511306-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511306-23-00.